Rockett M, Simpson G, Crossley R, Blowey S. Characteristics of pain in hospitalized medical patients, surgical patients, and outpatients attending a pain management centre. Br J Anaesth. 2013;110(6):1017–23.
Lin RJ, Reid MC, Chused AE, Evans AT. Quality assessment of acute inpatient pain management in an academic health center. Am J Hosp Palliat Care. 2014. doi:10.1177/1049909114546545.
Buchheit T, Van de Ven T, Shaw A. Epigenetics and the transition from acute to chronic pain. Pain Med. 2012;13(11):1474–90.
Apkarian AV, Baliki MN, Farmer MA. Predicting transition to chronic pain. Curr Opin Neurol. 2013;26(4):360–7.
Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg. 2003;97(2):534–40 (table of contents).
Fletcher D, Fermanian C, Mardaye A, Aegerter P, (SFAR) PaRACotFAaICS. A patient-based national survey on postoperative pain management in France reveals significant achievements and persistent challenges. Pain. 2008;137:441–51.
Maier C, Nestler N, Richter H, et al. The quality of pain management in German hospitals. Dtsch Arztebl Int. 2010;107(36):607–14.
Moskovitz B, Benson CJ, Patel AA, et al. Analgesic treatment of moderate-to-severe acute pain in the United States: patients’ perspectives in the physicians partnering against pain (P3) survey. J Opioid Manag. 2011;7(4):277–86.
Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2005(3):CD001133.
Brune K, Hinz B, Otterness I. Aspirin and acetaminophen: should they be available over the counter? Curr Rheumatol Rep. 2009;11(1):36–40.
Dajani EZ, Islam K. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J Physiol Pharmacol. 2008;59(Suppl 2):117–33.
Taylor R Jr, Lemtouni S, Weiss K, Pergolizzi JV Jr. Pain management in the elderly: an FDA safe use initiative expert panel’s view on preventable harm associated with NSAID therapy. Curr Gerontol Geriatr Res. 2012;2012:196159.
Amabile C, Bowman B. Overview of oral modified-release opioid products for the management of chronic pain. Ann Pharmacother. 2006;409:1327–35.
Rauck RL. What is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical review. Pain Pract. 2009;9(6):468–79.
McCarberg B, Barkin R. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001;8:181–6.
Ferrell B, Wisdom C, Wenzl C, Brown J. Effects of controlled-release morphine on quality of life for cancer pain. Oncol Nurs Forum. 1989;16:521–6.
Sullivan M. Will data destroy our faith in long-acting opioids? Pain Manag Nurs. 2014;155(5):881–8.
Pergolizzi JV Jr, Mercadante S, Echaburu AV, et al. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin. 2009;25(6):1517–28.
Gourlay G. Sustained relief after chronic pain. Pharmacokinetics of sustained release morphine. Clin Pharmacokinet. 1998;35:173–90.
Arkinstall W, Goughnour B, White J, Stewart J. Control of severe pain with sustained-release morphine tablets v. oral morphine solution. CMAJ. 1989;140:653–7.
Hale M, Fleischmann RM, Salzman RT, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain. 1999;15:179–83.
Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumat. 1999;26(4):862–9.
Klepstad P, Kaasa S, Jystad A, Hval B, Borchgrevink P. Immediate- or sustained-release morphine for dose finding during start of morphine to cancer patients: a randomized, double-blind trial. Pain Manag Nurs. 2003;101:193–8.
Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manag. 2003;26(5):1026–48.
Governale L. Outpatient prescription opioid utilization in the U.S., years 2000–2009. Rockville: Food & Drug Administration; 2010. http://www.fda.gov.ezproxy.welch.jhmi.edu/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementADvisoryCommittee/UCM220950.pdf. Accessed Nov 8, 2014.
Gould HJ 3rd, Paul D. Hydrocodone extended-release: pharmacodynamics, pharmacokinetics and behavioral pharmacology of a controversy. Pharmacol Res. 2015;91:99–103.
Manchikanti L, Atluri S, Candido KD, et al. Zohydro approval by food and drug administration: controversial or frightening? Pain Physician. 2014;17(4):E437–50.
Olsen Y, Sharfstein JM. Chronic pain, addiction, and Zohydro. N Engl J Med. 2014;370(22):2061–3.
Raffa RB. Pharmacology of oral combination analgesics: rational therapy for pain. J Clin Pharm Ther. 2001;26(4):257–64.
Gatti A, Sabato E, Di Paolo AR, Mammucari M, Sabato AF. Oxycodone/paracetamol: a low-dose synergic combination useful in different types of pain. Clin Drug Investig. 2010;30(Suppl 2):3–14.
Gammaitoni AR, Galer BS, Lacouture P, Domingos J, Schlagheck T. Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain. Pain Med. 2003;4(1):21–30.
Raffaeli W, Pari C, Corvetta A, et al. Oxycodone/acetaminophen at low dosage: an alternative pain treatment for patients with rheumatoid arthritis. J Opioid Manag. 2010;6(1):40–6.
Gatti A, Sabato AF, Carucci A, Bertini L, Mammucari M, Occhioni R. Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. Clin Drug Investig. 2009;29(Suppl 1):31–40.
Corsinovi L, Martinelli E, Fonte G, et al. Efficacy of oxycodone/acetaminophen and codeine/acetaminophen vs. conventional therapy in elderly women with persistent, moderate to severe osteoarthritis-related pain. Arch Gerontol Geriatr. 2009;49(3):378–82.
Gaskell H, Derry S, Moore RA, McQuay HJ. Single dose oral oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009(3):CD002763.
Edwards JE, Moore RA, McQuay HJ. Single dose oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain. Cochrane Database Syst Rev. 2000(4):CD002763.
Kogan A, Medalion B, Raanani E, et al. Early oral analgesia after fast-track cardiac anesthesia. Can J Anaesth. 2007;54(4):254–61.
Chang DJ, Desjardins PJ, Bird SR, et al. Comparison of rofecoxib and a multidose oxycodone/acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial. Curr Med Res Opin. 2004;20(6):939–49.
Lovell SJ, Taira T, Rodriguez E, Wackett A, Gulla J, Singer AJ. Comparison of valdecoxib and an oxycodone-acetaminophen combination for acute musculoskeletal pain in the emergency department: a randomized controlled trial. Acad Emerg Med. 2004;11(12):1278–82.
Sima L, Fang WX, Wu XM, Li F. Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial. J Clin Pharm Ther. 2012;37(1):27–31.
Singla N, Barrett T, Sisk L, Kostenbader K, Young J, Giuliani M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of MNK-795, a dual-layer, biphasic, immediate-release and extended-release combination analgesic for acute pain. Curr Med Res Opin. 2014;30(3):349–59.
Singla N, Barrett T, Sisk L, Kostenbader K, Young J. Assessment of the safety and efficacy of extended-release oxycodone/acetaminophen, for 14 days postsurgery. Curr Med Res Opin. 2014;30(12):2571–8
Kaufman D, Kelly J, Rosenberg L, Anderson T, Mitchell A. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287(3):337–44.
Vernacchio L, Kelly J, Kaufman D, Michell A. Medication use among children <12 years of age in the United States: results from the Slone Survey. Pediatrics. 2009;124:446–54.
Kuehn B. FDA focuses on drugs and liver damage: labeling and other changes for acetaminophen. JAMA. 2009;302:369–71.
Krenzelok E, The FDA. Acetaminophen advisory committee meeting–what is the future of acetaminophen in the United States? The perspective of a committee member. Clin Toxicol. 2009;47:784–9.
DeDea L. FDA limits acetaminophen; risk of death with tigecycline. JAAPA. 2012;25:16.
Stumpf J, Skyles A, Alaniz C, Erickson S. Knowledge of appropriate acetaminophen doses and potential toxicities in an adult clinic population. J Am Pharm Assoc. 2007;47:35–41.
Hornsby L, Whitley H, Hester E, Thompson MM, Donaldson A. Survey of patient knowledge related to acetaminophen recognition, dosing, and toxicity. J Am Pharm Assoc. 2010;50:485–9.
Herndon C, Dankenbring D. Patient perception and knowledge of acetaminophen in a large family medicine service. J Pain Palliat Care Pharmacother. 2014;28:109–16.
Duh MS, Vekeman F, Korves C, et al. Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications. Pain Med. 2010;11(11):1718–25.
Extended-release oxycodone and acetaminophen. Xartemis XR. Med Lett Drugs Ther. 2014;56(1447):59–60.
Devarakonda K, Morton T, Margulis R, Giuliani M, Barrett T. Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions. Drug Des Devel Ther. 2014;8:1125–34.
Mallinckrodt I. XARTEMIS XR oxycodone hydrochloride and acetaminophen tablet, highlights of prescribing information. Hazelwood: Mallinckrodt Brand Pharmaceuticals Inc; 2014.
Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64(5):669–81.
Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66(3):377–88.
Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil. 2008;16(2):137–62.
American Geriatrics Society. AGS Clinical Practice Guideline: pharmacological management of persistent pain in older persons. New York: American Geriatrics Society; 2013. http://www.americangeriatrics.org/health_care_professionals/clinical_practice/clinical_guidelines_recommendations/persistent_pain_executive_summary. Cited Dec 14, 2013.
Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8(4):287–313.
Manchikanti L, Atluri S, Hansen H, et al. Opioids in chronic noncancer pain: have we reached a boiling point yet? Pain Physician. 2014;17(1):E1–10.
Manchikanti L, Benyamin R, Datta S, Vallejo R, Smith H. Opioids in chronic noncancer pain. Expert Rev Neurother. 2010;10(5):775–89.
Manchikanti L, Benyamin RM. Long-term opioid therapy. Pain Pract. 2009;9(2):164 (author reply).
DeRemer CE, Fleming VH, Brown S, May JR. Evaluation of pain management documentation. S Med J. 2011;104(9):629–33.
Stanos S. Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids. Phys Sportsmed. 2012;40(4):12–20.
Mercadante S, Craig D, Giarratano A. US food and drug administration’s risk evaluation and mitigation strategy for extended-release and long-acting opioids: pros and cons, and a European perspective. Drugs. 2012;72(18):2327–32.
Braden JB, Russo J, Fan MY, Edlund MJ, Martin BC, DeVries A, et al. Emergency department visits among recipients of chronic opioid therapy. Arch Intern Med. 2010;170(16):1425–32.
Morton T, Kostenbader K, Montgomery J, Devarakonda K, Barrett T, Webster L. Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial. Postgrad Med. 2014;126(4):20–32.
Peppin JF, Coleman JJ, Kirsh KL. Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management. Issues Law Med. 2011;27(2):91–119.
Pergolizzi JV Jr, Lequang JA. Abuse-deterrent formulations of opioid analgesics. Pain Pract. 2014;14(3):204–6.
Schaeffer T. Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics. J Med Toxicol. 2012;8(4):400–7.
Mallinckrodt, editor. Evaluation of the tamper-resistant properties of MNK-795 controlled-release oxycodone/acetaminophen tablets (CR OC/APAP). Las Vegas: PAINWeek; 2013.
Reid N, Mazer-Amirshahi M, Clancy C, James L, van den Anker J. Elevated acetaminophen concentration measured after nasal insufflation of Percocet®. J Emerg Med. 2013;45(5):683–5.
Rosenbaum CD, Boyle KL, Boyer EW. Nasopharyngeal necrosis after chronic opioid (oxycodone/acetaminophen) insufflation. J Med Toxicol. 2012;8(2):240–1.
Alvarez L. Florida shutting ‘pill mill’ clinics. The New York Times. Sect. U.S.; 2011. Aug 31, 2011.
Reisman RM, Shenoy PJ, Atherly AJ, Flowers CR. Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring program efficacy. Subst Abuse. 2009;3:41–51.